Compare Abeona Therapeutics Inc (ABEO) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Berkshire Hathaway Inc Class B — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Berkshire Hathaway Inc Class B trades at $501.06. Which is the better fit depends on your goals.
| ABEO | BRK.B | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Financials |
52-Week High | $7.23 | $513.70 |
52-Week Low | $4.17 | $459.10 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BRK.B trades at $502.09, down 0.91% today, with a bullish technical signal driven by moving averages. Support levels are near $494–$501, while resistance sits at $509–$517. Analyst consensus is positive, with 57% buy ratings, though key financial ratios like P/E and P/B are not provided in the data. The stock shows strong momentum with ADX indicating a robust trend.
The outlook for BRK.B is cautiously optimistic given bullish technicals and analyst support, but the absence of recent fundamental data limits valuation clarity. Risks include market volatility and reliance on broader economic conditions. Investors should await updated earnings reports for a fuller picture of intrinsic value and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
